[The use of a virazole aerosol in young children with a respiratory syncytial virus infection].
The therapeutic effect of aerosol virasol was studied in young infants suffering from RS virus infection with concomitant broncho-obstructive syndrome. The study involved 60 children between 1 month and 4 years of age of whom 30 were treated with virasol and another 30 made a control group. Virasol was shown to reduce the severity of the clinical picture to a considerable degree and speed up the recovery in infants with RS virus disease. Virasol is recommended for inhalation treatment of infants with RS virus infection and concomitant broncho-obstructive syndrome. The daily dose of virasol is 10 mg per kilo of body weight. The duration of one course is 3 to 5 days.
Cheshik
S G
SG
Vartanian
R V
RV
Ivanova
L A
LA
Kisteneva
L B
LB
Galegov
G A
GA
D000336:Aerosols; D002675:Child, Preschool; D004341:Drug Evaluation; D006801:Humans; D007223:Infant; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D012074:Remission Induction; D012136:Respiratory Syncytial Viruses; D010253:Respirovirus Infections / Q000188:drug therapy* / Q000378:metabolism; D012254:Ribavirin / Q000008:administration & dosage*; D013997:Time Factors
D000336:Aerosols; D012254:Ribavirin
Primenenie aérozolia virazola u deteĭ rannego vozrasta s respiratorno-sintsitial'noĭ virusnoĭ infektsieĭ.